Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death

A PROTEUS substudy shows that perioperative apalutamide plus androgen deprivation therapy (ADT) combined with prostatectomy reduces the risk of metastasis or death in high-risk prostate cancer patients. The 1:3 randomized study enrolled 408 newly diagnosed patients with high-risk localized or locally advanced disease; compared with radical prostatectomy alone, at a median follow-up of 37.8 months, event-free survival improved by 62%, the risk of metastasis or death fell by 51%, the risk of starting subsequent treatment fell by 71%, and adverse events were consistent with prior studies.